Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	427.92B
Revenue (ttm)	700.31B
Net Income (ttm)	-24.22B
Shares Out	9.16M
EPS (ttm)	-9,556.22
PE Ratio	n/a
Forward PE	11.38
Dividend	672.82 (1.44%)
Ex-Dividend Date	Mar 13, 2025

Volume	12,413
Average Volume	29,940
Open	46,550
Previous Close	46,500
Day's Range	46,500 - 47,800
52-Week Range	44,657 - 79,118
Beta	0.55
RSI	44.36
Earnings Date	Apr 25, 2025

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,687
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2023, Dong-A ST's revenue was 663.98 billion, an increase of 4.50% compared to the previous year's 635.39 billion. Earnings were 11.12 billion, a decrease of -17.93%.